Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0220723 (
PCA
)
4,687
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In porcine (
PCA
) and bovine (BCA) coronary arterial strips, epidermal growth factor-urogastrone (EGF-URO) caused an endothelium-independent Ca-requiring contractile response that could not be attributed to the secondary release of agonists from neural elements. In these tissues, EGF-URO also potentiated the contractile actions of other agonists (prostaglandin F2 alpha, KCl or norepinephrine). Nonetheless, the responsiveness of the
PCA
and BCA preparations differed markedly in terms of 1) their sensitivity to indomethacin and dexamethasone (indomethacin and dexamethasone abrogated the
PCA
but not the BCA response), 2) their desensitization properties (the BCA rapidly desensitized, whereas the
PCA
did not) and 3) the order of potencies for EGF-URO and
transforming growth factor-alpha
(
TGF-alpha
) (in the
PCA
, EGF-URO was more potent than
TGF-alpha
, whereas in the BCA, the potency of
TGF-alpha
was greater than or equal to that of EGF-URO). Taken together our data document the presence of two distinct receptor signaling systems for EGF-URO in the
PCA
and BCA preparations, and our results support the hypothesis that distinct receptor subtypes for EGF-URO may be present in these two tissues.
...
PMID:Distinct coronary artery receptor systems for epidermal growth factor-urogastrone. 231 70